Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): Outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Authors

• G Curigliano, University of Milano
• N A Bagegni, Washington University School of Medicine in St. Louis
• et al.

Journal

Annals of Oncology

Publication Date

6-1-2026

Volume

37

Issue

6

First Page

849

Last Page

860

Document Type

Open Access Publication

DOI

10.1016/j.annonc.2026.02.015

Rights and Permissions

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-Ćwik A, Schwaederle M, Anand S, Bardia A. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol. 2026 Jun;37(6):849-860. doi: 10.1016/j.annonc.2026.02.015. © 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Curigliano, G; Bagegni, N A; and et al., "Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): Outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease." Annals of Oncology. 37, 6. 849 - 860. (2026).
https://digitalcommons.wustl.edu/oa_4/6821

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.